cell carcinoma in situ (CIS) and/or unresectable papillary superficial bladder cancer. III.
Evaluate a dose-response effect and choose an appropriate dose for further clinical study.
are performed at 3 and/or 6 months, and thereafter if clinically applicable.
PROJECTED ACCRUAL: 19 evaluable patients will be enrolled.